Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors

R. Plummer, R. E. Sanborn, E. G.E. de Vries, P. Lorusso, H. T. Arkenau, N. Uboha, J. Wydmanski, M. J. Fidler, V. Boni, J. Garcia-Corbacho, R. Humphrey, M. Will, K. A. Autio, A. B. El-Khoueiry, C. W. Menke-van der Houven van Oordt, F. Thistlethwaite

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)viii143
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Publication statusPublished - 1 Oct 2018

Cite this